haloperidol and Childhood Schizophrenia studies

Haloperidol: A phenyl-piperidinyl-butyrophenone that is used primarily to treat SCHIZOPHRENIA and other PSYCHOSES. It is also used in schizoaffective disorder, DELUSIONAL DISORDERS, ballism, and TOURETTE SYNDROME (a drug of choice) and occasionally as adjunctive therapy in INTELLECTUAL DISABILITY and the chorea of HUNTINGTON DISEASE. It is a potent antiemetic and is used in the treatment of intractable HICCUPS. (From AMA Drug Evaluations Annual, 1994, p279)
haloperidol : A compound composed of a central piperidine structure with hydroxy and p-chlorophenyl substituents at position 4 and an N-linked p-fluorobutyrophenone moiety.

Research Excerpts

Excerpt	Relevance	Reference
"Plasma clozapine and haloperidol concentrations were studied in adolescents being treated for childhood-onset schizophrenia."	9.07	Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. ( Albus, KE; Frazier, JA; Gordon, CT; Grothe, DR; McKenna, K; Piscitelli, SC; Rapoport, JL, 1994)
"Plasma clozapine and haloperidol concentrations were studied in adolescents being treated for childhood-onset schizophrenia."	5.07	Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. ( Albus, KE; Frazier, JA; Gordon, CT; Grothe, DR; McKenna, K; Piscitelli, SC; Rapoport, JL, 1994)
"However, neutropenia and seizures were major concerns."	2.68	Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. ( Alaghband-Rad, J; Albus, KE; Frazier, JA; Gordon, CT; Hamburger, SD; Jacobsen, LK; Kumra, S; Lenane, MC; McKenna, K; Rapoport, JL; Smith, AK, 1996)
"Fever is generally considered to be an essential feature of neuroleptic malignant syndrome (NMS)."	1.29	Case study: neuroleptic malignant syndrome without pyrexia. ( Hynes, AF; Vickar, EL, 1996)

Research

Studies (18)

Authors

Clinical Trials (1)

Trial Overview

Trial Outcomes

Change in Body Mass Index (BMI)

Timeframe	Studies, this research(%)	All Research%
pre-1990	10 (55.56)	18.7374
1990's	7 (38.89)	18.2507
2000's	1 (5.56)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors	Studies
Kumra, S	2
Oberstar, JV	1
Sikich, L	1
Findling, RL	1
McClellan, JM	1
Vinogradov, S	1
Charles Schulz, S	1
Meyers, B	1
Tune, LE	1
Coyle, JT	1
Spencer, EK	1
Campbell, M	1
Gordon, CT	5
Frazier, JA	5
McKenna, K	5
Giedd, J	1
Zametkin, A	1
Zahn, T	1
Hommer, D	1
Hong, W	1
Kaysen, D	1
Albus, KE	3
Piscitelli, SC	1
Grothe, DR	1
Rapoport, JL	4
Lenane, MC	3
Jih, D	1
Hynes, AF	1
Vickar, EL	1
Jacobsen, LK	2
Hamburger, SD	2
Smith, AK	1
Alaghband-Rad, J	1
Malhotra, AK	1
Karoum, F	1
Pickar, D	1
Potter, WZ	1
Heath, A	1
Geller, B	1
Greydanus, DE	1
Sheinbein, ML	1
Wiggins, KM	1
McDaniel, KD	1
Semanovskaia, EI	1
Eggers, C	1
Faretra, G	1
Dooher, L	1
Dowling, J	1
Le Vann, LJ	1
Holstein, AP	1
Chen, CH	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
Childhood Onset Psychotic Disorders: Characterization and Treatment With Atypical Neuroleptics[NCT00001656]	Phase 4	25 participants (Actual)	Interventional	1997-06-30	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

BMI is calculated by the following formula: weight (in kilograms) divided by the square of the height (in meters) (NCT00001656)
Timeframe: 8 week double-blind study period; baseline and 8 weeks

Change in Bunney-Hamburg Rating Scale for Depression

Intervention	kg/m² (Mean)
Olanzapine Group	1.4
Clozapine Group	1.6

Measures change in severity of depression; Minimum score = 0; maximum score = 7; lower score is considered a better outcome. (NCT00001656)
Timeframe: 8 week double-blind study period; baseline and 8 weeks

Change in Bunney-Hamburg Rating Scale for Mania

Intervention	Scores on a scale (Mean)
Olanzapine Group	0.4
Clozapine Group	0.2

Measures change in the severity of mania; Minimum score = 0; maximum score = 7; lower score is considered a better outcome. (NCT00001656)
Timeframe: 8 week double-blind study period; baseline and 8 weeks

Change in Extrapyramidal Movements as Measured by the Abnormal Involuntary Movements Scale (AIMS)

Intervention	Scores on a scale (Mean)
Olanzapine Group	-0.4
Clozapine Group	-0.8

minimum score = 10; maximum score = 50; lower score is considered a more favorable outcome (NCT00001656)
Timeframe: 8 week double-blind study period; baseline and 8 weeks

Change in Extrapyramidal Movements as Measured by the Simpson Angus Scale Score

Intervention	scores on a scale (Median)
Olanzapine Group	0
Clozapine Group	0

minimum score = 10; maximum score = 90; lower score considered a more favorable outcome (NCT00001656)
Timeframe: 8 week double-blind study period; baseline and 8 weeks

Change in the Brief Psychiatric Rating Scale-24

Intervention	scores on a scale (Median)
Olanzapine Group	0
Clozapine Group	0

A 24-item scale measuring change in interpersonal behaviors, mood, psychosis, anxiety, speech, sleep, orientation and physical activity. Lowest score = 24; highest score = 168; lower score is considered a better outcome. (NCT00001656)
Timeframe: 8 week double-blind study period; baseline and 8 weeks

Change in the Bunney-Hamburg Rating Scale for Anxiety

Intervention	Scores on a scale (Mean)
Olanzapine Group	-13
Clozapine Group	-19

Measures change in the severity of anxiety; Minimum score = 0; maximum score = 7; lower score is considered a better outcome. (NCT00001656)
Timeframe: 8 week double-blind study period; baseline and 8 weeks

Change in the Bunney-Hamburg Rating Scale for Psychosis

Intervention	Scores on a scale (Mean)
Olanzapine Group	-0.5
Clozapine Group	0.6

Measures change in psychosis severity; Minimum score = 0; maximum score = 7; lower score is considered a better outcome. (NCT00001656)
Timeframe: 8 week double-blind study period; baseline and 8 weeks

Change in the Clinical Global Impression Severity of Symptoms Scale

Intervention	Scores on a scale (Mean)
Olanzapine Group	-3.1
Clozapine Group	-4

Measures change in the severity of symptoms; Minimum score = 1; maximum score = 7; lower score is considered a better outcome. (NCT00001656)
Timeframe: 8 week double-blind study period; baseline and 8 weeks

Change in the Scale for the Assessment of Negative Symptoms

Intervention	Scores on a scale (Mean)
Olanzapine Group	-0.6
Clozapine Group	-1.6

Measures change in affective flattening or blunting, alogia, avolition/apathy, anhedonia/asociality, attention; minimum score = 0; maximum score = 125; lower values are considered a better outcome (NCT00001656)
Timeframe: 8 week double-blind study period; baseline and 8 weeks

Change in the Scale for the Assessment of Positive Symptoms

Intervention	Scores on a scale (Mean)
Olanzapine Group	-14
Clozapine Group	-25

Measures change in hallucinations, delusions, bizarre behavior, and thought organization. Minimum score = 0; maximum score = 170; lower score is considered a better outcome. (NCT00001656)
Timeframe: 8 week double-blind study period; baseline and 8 weeks

Article	Year
Efficacy and tolerability of second-generation antipsychotics in children and adolescents with schizophrenia. Schizophrenia bulletin, 2008, Volume: 34, Issue:1 Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Disorders of Excessive Som	2008
Children with schizophrenia: diagnosis, phenomenology, and pharmacotherapy. Schizophrenia bulletin, 1994, Volume: 20, Issue:4 Topics: Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Blind Method; Female; Haloperidol;	1994
Psychiatric drug treatment in children. The Journal of the Maine Medical Association, 1979, Volume: 70, Issue:5 Topics: Adolescent; Amphetamines; Antipsychotic Agents; Anxiety; Autistic Disorder; Behavior Therapy; Child;	1979
[Prepsychotic states in infancy (author's transl)]. Monatsschrift fur Kinderheilkunde, 1974, Volume: 122, Issue:11 Topics: Affective Symptoms; Age Factors; Child; Child Behavior Disorders; Child Development; Child, Preschoo	1974

Article	Year
Children with schizophrenia: diagnosis, phenomenology, and pharmacotherapy. Schizophrenia bulletin, 1994, Volume: 20, Issue:4 Topics: Child; Child, Preschool; Dose-Response Relationship, Drug; Double-Blind Method; Female; Haloperidol;	1994
Childhood-onset schizophrenia: an NIMH study in progress. Schizophrenia bulletin, 1994, Volume: 20, Issue:4 Topics: Adolescent; Brain; Brain Mapping; Child; Clozapine; Diagnostic Imaging; Double-Blind Method; Female;	1994
Plasma clozapine and haloperidol concentrations in adolescents with childhood-onset schizophrenia: association with response. The Journal of clinical psychiatry, 1994, Volume: 55 Suppl B Topics: Adolescent; Age of Onset; Child; Clozapine; Drug Administration Schedule; Female; Haloperidol; Human	1994
An open trial of clozapine in 11 adolescents with childhood-onset schizophrenia. Journal of the American Academy of Child and Adolescent Psychiatry, 1994, Volume: 33, Issue:5 Topics: Adolescent; Child; Clozapine; Double-Blind Method; Female; Haloperidol; Humans; Male; Psychiatric St	1994
Childhood-onset schizophrenia. A double-blind clozapine-haloperidol comparison. Archives of general psychiatry, 1996, Volume: 53, Issue:12 Topics: Adolescent; Age Factors; Age of Onset; Child; Child, Preschool; Clozapine; Double-Blind Method; Drug	1996

Article	Year
Clinical response and serum neuroleptic levels in childhood schizophrenia. The American journal of psychiatry, 1980, Volume: 137, Issue:4 Topics: Adolescent; Dose-Response Relationship, Drug; Haloperidol; Humans; Male; Schizophrenia, Childhood	1980
Case study: neuroleptic malignant syndrome without pyrexia. Journal of the American Academy of Child and Adolescent Psychiatry, 1996, Volume: 35, Issue:7 Topics: Antipsychotic Agents; Child; Dose-Response Relationship, Drug; Drug Administration Schedule; Fever;	1996
Cerebrospinal fluid monoamine metabolites in childhood-onset schizophrenia. The American journal of psychiatry, 1997, Volume: 154, Issue:1 Topics: Adolescent; Age of Onset; Child; Clozapine; Haloperidol; Homovanillic Acid; Humans; Hydroxyindoleace	1997
Haloperidol-induced comatose state with hyperthermia and rigidity in adolescence: two case reports with a literature review. The Journal of clinical psychiatry, 1979, Volume: 40, Issue:2 Topics: Adolescent; Child; Child Behavior Disorders; Coma; Female; Fever; Haloperidol; Humans; Male; Muscle	1979
An operant counting scale for children: A preliminary methodological psychoactive-drug case study. Child psychiatry and human development, 1975,Spring, Volume: 5, Issue:3 Topics: Adolescent; Aggression; Anxiety Disorders; Child; Child Behavior Disorders; Dependency, Psychologica	1975
Pharmacologic treatment of psychiatric and neurodevelopmental disorders in children and adolescents (Part 2). Clinical pediatrics, 1986, Volume: 25, Issue:3 Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Benzodiazepines; Child; Chlorpromazine; Haloper	1986
[Affective disorders in the course of treatment with neuroleptics of children and adolescents with schizophrenia]. Zhurnal nevropatologii i psikhiatrii imeni S.S. Korsakova (Moscow, Russia : 1952), 1967, Volume: 67, Issue:10 Topics: Adolescent; Affect; Child; Child, Preschool; Chlorpromazine; Depression; Haloperidol; Humans; Moveme	1967
Comparison of haloperidol and fluphenazine in disturbed children. The American journal of psychiatry, 1970, Volume: 126, Issue:11 Topics: Aggression; Anxiety; Autistic Disorder; Child; Child, Preschool; Female; Fluphenazine; Haloperidol;	1970
Haloperidol in the treatment of behavioural disorders in children and adolescents. Canadian Psychiatric Association journal, 1969, Volume: 14, Issue:2 Topics: Adolescent; Adult; Attention; Child; Child Behavior Disorders; Extrapyramidal Tracts; Female; Halope	1969
Haloperidol--a preliminary clinical study. The American journal of psychiatry, 1965, Volume: 122, Issue:4 Topics: Depressive Disorder, Major; Extrapyramidal Tracts; Haloperidol; Humans; Paranoid Disorders; Schizoph	1965

haloperidol and Childhood Schizophrenia